Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01453946 · ClinicalTrials.gov registry record · Phase 3

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

A Phase 3 study of Crohn's Disease, sponsored by Padagis.

Completed
Registry status
Phase 3
Development phase
55
Enrollment target
19
Study locations

NCT01453946: Completed Phase 3 study of Crohn's Disease, sponsored by Padagis.

NCT01453946 is a Phase 3 study of Crohn's Disease that has completed, run by Padagis. The registered enrollment target is 55 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (98% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01453946, a Phase 3 study of Crohn's Disease, has completed, sponsored by Padagis.

COMPLETED
Registry status
Phase 3
Development phase
55 participants
Enrollment target
19
Study locations

Study Summary

A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.

Primary Outcome

Any kind of adverse event

Conditions Studied

Interventions

  • DRUG Entocort

Study Locations (19)

Other

  • Research Site - München
  • Research Site - Nuremberg
  • Research Site - Florence
  • Research Site - Messina
  • Research Site - Roma
  • Research Site - Krakow
  • Research Site - Lodz
  • Research Site - Rzeszów
  • Research Site - Warsaw
  • Research Site - Wroclaw

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Oak Lawn

Massachusetts

  • Research Site - Newton

Minnesota

  • Research Site - Saint Paul

New Jersey

  • Research Site - Mays Landing

New York

  • Research Site - Buffalo

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2011-12
Est. Completion 2014-02
Phase Phase 3
Padagis

17 total trials

What the finished NCT01453946 record still lists

NCT01453946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Entocort is the first listed.

NCT01453946 lists 19 locations in 10 states (Other, Georgia, Illinois).

Frequently Asked Questions

What is clinical trial NCT01453946 about?

NCT01453946 is a clinical study titled "Safety and Maintenance Study of Entocort for Children With Crohn's Disease". A Safety for Maintenance of Entocort EC for children with mild to moderate Crohn's Disease.

What is the current status of trial NCT01453946?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2011-12. Estimated completion is 2014-02.

What conditions does trial NCT01453946 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT01453946?

The interventions under investigation include: Entocort (DRUG).

Who is sponsoring clinical trial NCT01453946?

This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01453946 being conducted?

This trial has 19 study locations across Georgia, Illinois, Massachusetts, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01453946's enrollment target sits among peer trials

55 81st of 105 higher than 25 of 105 other Crohn's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01453946, the US trial registry maintained by the National Library of Medicine. NCT01453946 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.